Relevance of Hybridoma Technology to the Covid-19 immunization era: Monoclonal Antibodies' methodologies, applications, pros, and cons

Achim Cchitvsanzwhoh Satheka

抽象的な

Relevance of Hybridoma Technology to the Covid-19 immunization era: Monoclonal Antibodies' methodologies, applications, pros, and cons

Achim Cchitvsanzwhoh Satheka

Coronavirus disease 2019 (Covid-19) has claimed over 2.5 million lives around the world as of early March 2021 and 114 million people have been infected with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) which is a strain of coronavirus that causes Covid-19. Pharmaceutical companies have seen opportunities in using monoclonal antibodies (MAbs) to neutralize SARS-Cov-2 as masses await vaccination.

免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません

次世代シーケンシングとアプリケーションのジャーナル

抽象的な

Relevance of Hybridoma Technology to the Covid-19 immunization era: Monoclonal Antibodies' methodologies, applications, pros, and cons

ジャーナルのハイライト

索引付けされたジャーナル